121 related articles for article (PubMed ID: 7540857)
1. Clinicopathological correlates of CD56 expression in multiple myeloma: a unique entity?
Mathew P; Ahmann GJ; Witzig TE; Roche PC; Kyle RA; Greipp PR
Br J Haematol; 1995 Jun; 90(2):459-61. PubMed ID: 7540857
[TBL] [Abstract][Full Text] [Related]
2. Analysis of multidrug-resistance (MDR-1) glycoprotein and CD56 expression to separate monoclonal gammopathy from multiple myeloma.
Sonneveld P; Durie BG; Lokhorst HM; Frutiger Y; Schoester M; Vela EE
Br J Haematol; 1993 Jan; 83(1):63-7. PubMed ID: 7679588
[TBL] [Abstract][Full Text] [Related]
3. Increased expression of CD56 and HLA/DR antigens in CD2+ cells from multiple myeloma patients.
Lapeña P; Prieto A; Garcia-Suarez J; Reyes E; San Miguel J; Jorda J; Alvarez-Mon M
Am J Hematol; 1994 Jun; 46(2):158-9. PubMed ID: 7513496
[No Abstract] [Full Text] [Related]
4. Plasma cells in multiple myeloma express a natural killer cell-associated antigen: CD56 (NKH-1; Leu-19).
Van Camp B; Durie BG; Spier C; De Waele M; Van Riet I; Vela E; Frutiger Y; Richter L; Grogan TM
Blood; 1990 Jul; 76(2):377-82. PubMed ID: 1695113
[TBL] [Abstract][Full Text] [Related]
5. Prognostic Relevance of Concordant Expression CD69 and CD56 in Response to Bortezomib Combination Therapy in Multiple Myeloma Patients.
ElMenshawy N; Farag NA; Atia DM; Abousamra N; Shahin D; Fawzi E; Ghazi H; El-Kott AF; Eissa M
Cancer Invest; 2021 Oct; 39(9):777-782. PubMed ID: 34344244
[TBL] [Abstract][Full Text] [Related]
6. CD19 and immunophenotype of bone marrow plasma cells in monoclonal gammopathy of undetermined significance.
Zandecki M; Facon T; Bernardi F; Izydorczyk V; Dupond L; François M; Reade R; Iaru T; Bauters F; Cosson A
J Clin Pathol; 1995 Jun; 48(6):548-52. PubMed ID: 7545187
[TBL] [Abstract][Full Text] [Related]
7. Neural cell adhesion molecule expression in plasma cells in bone marrow biopsies and aspirates allows discrimination between multiple myeloma, monoclonal gammopathy of uncertain significance and polyclonal plasmacytosis.
Martín P; Santón A; Bellas C
Histopathology; 2004 Apr; 44(4):375-80. PubMed ID: 15049904
[TBL] [Abstract][Full Text] [Related]
8. Expression of adhesion molecules LFA-3 and N-CAM on normal and malignant human plasma cells.
Barker HF; Hamilton MS; Ball J; Drew M; Franklin IM
Br J Haematol; 1992 Jul; 81(3):331-5. PubMed ID: 1382543
[TBL] [Abstract][Full Text] [Related]
9. Clinicopathological and prognostic characteristics of CD56-negative multiple myeloma.
Sahara N; Takeshita A; Shigeno K; Fujisawa S; Takeshita K; Naito K; Ihara M; Ono T; Tamashima S; Nara K; Ohnishi K; Ohno R
Br J Haematol; 2002 Jun; 117(4):882-5. PubMed ID: 12060125
[TBL] [Abstract][Full Text] [Related]
10. Expression of cytoadhesion molecules (CD56, CD54, CD18 and CD29) by myeloma plasma cells.
Van Riet I; De Waele M; Remels L; Lacor P; Schots R; Van Camp B
Br J Haematol; 1991 Nov; 79(3):421-7. PubMed ID: 1721526
[TBL] [Abstract][Full Text] [Related]
11. Immunophenotypic and DNA content characteristics of plasma cells in multiple myeloma and monoclonal gammopathy of undetermined significance.
Almeida J; Orfao A; Mateo G; Ocqueteau M; García-Sanz R; Moro MJ; Hernandez J; Ortega F; Borrego D; Barez A; Mejido M; San Miguel JF
Pathol Biol (Paris); 1999 Feb; 47(2):119-27. PubMed ID: 10192879
[TBL] [Abstract][Full Text] [Related]
12. Expression of CD28 and CD40 in human myeloma cells: a comparative study with normal plasma cells.
Pellat-Deceunynck C; Bataille R; Robillard N; Harousseau JL; Rapp MJ; Juge-Morineau N; Wijdenes J; Amiot M
Blood; 1994 Oct; 84(8):2597-603. PubMed ID: 7522634
[TBL] [Abstract][Full Text] [Related]
13. Clinicopathological correlates of plasma cell CD56 (NCAM) expression in multiple myeloma.
Kraj M; Sokołowska U; Kopeć-Szlezak J; Pogłód R; Kruk B; Woźniak J; Szpila T
Leuk Lymphoma; 2008 Feb; 49(2):298-305. PubMed ID: 18231917
[TBL] [Abstract][Full Text] [Related]
14. Immunophenotypic characterization of plasma cells from monoclonal gammopathy of undetermined significance patients. Implications for the differential diagnosis between MGUS and multiple myeloma.
Ocqueteau M; Orfao A; Almeida J; Bladé J; González M; García-Sanz R; López-Berges C; Moro MJ; Hernández J; Escribano L; Caballero D; Rozman M; San Miguel JF
Am J Pathol; 1998 Jun; 152(6):1655-65. PubMed ID: 9626070
[TBL] [Abstract][Full Text] [Related]
15. Analysis of natural killer-associated antigens in peripheral blood and bone marrow of multiple myeloma patients and prognostic implications.
García-Sanz R; González M; Orfão A; Moro MJ; Hernández JM; Borrego D; Carnero M; Casanova F; Bárez A; Jiménez R; Portero JA; San Miguel JF
Br J Haematol; 1996 Apr; 93(1):81-8. PubMed ID: 8611480
[TBL] [Abstract][Full Text] [Related]
16. Correlation of plasma cell percentages by CD138 immunohistochemistry, cyclin D1 status, and CD56 expression with clinical parameters and overall survival in plasma cell myeloma.
Dunphy CH; Nies MK; Gabriel DA
Appl Immunohistochem Mol Morphol; 2007 Sep; 15(3):248-54. PubMed ID: 17721267
[TBL] [Abstract][Full Text] [Related]
17. Multiparameter immunophenotyping by flow cytometry as a diagnostic tool in multiple myeloma and monoclonal gammopathy of undetermined significance.
Carulli G; Ottaviano V; Cannizzo E; Giuntini S; Manetti C; Ciancia EM; Azzarà A
Clin Ter; 2012; 163(5):387-92. PubMed ID: 23099966
[TBL] [Abstract][Full Text] [Related]
18. Leu-19 in myeloma--a new role for an old antibody.
Wetter O; Brandhorst D; Reiter W
Eur J Cancer; 1990 Apr; 26(4):541. PubMed ID: 1694090
[No Abstract] [Full Text] [Related]
19. Prognostic relevance of CD56 expression in multiple myeloma: a study including 107 cases treated with high-dose melphalan-based chemotherapy and autologous stem cell transplant.
Chang H; Samiee S; Yi QL
Leuk Lymphoma; 2006 Jan; 47(1):43-7. PubMed ID: 16321826
[TBL] [Abstract][Full Text] [Related]
20. Multiple myeloma with coexpression of myeloid and natural killer cell antigens.
Drach J; Gattringer C; Huber H
Blood; 1990 Jul; 76(1):265-6. PubMed ID: 1694700
[No Abstract] [Full Text] [Related]
[Next] [New Search]
